Supriya Lifescience Limited has informed the Exchange regarding a press release dated December 09, 2024, titled "Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval & Atorvastatin patent filing".
Supriya Lifescience Limited has informed the Exchange regarding a press release dated December 09, 2024, titled "Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval & Atorvastatin patent filing".